Skip navigation
Home
Browse
Communities
& Collections
Browse Items by:
Issue Date
Author
Title
Advisor
Help
Sign on to:
My DSpace
Receive email
updates
Edit Profile
Adelaide Research & Scholarship
Adelaide Research & Scholarship
Search
Search:
All collections
Schools and Disciplines
School of Medicine
Medicine
Medicine publications
for
Current filters:
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Start a new search
Add filters:
Use filters to refine the search results.
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Results 1-8 of 8 (Search time: 0.002 seconds).
previous
1
next
Item hits:
Preview
Issue Date
Title
Author(s)
2009
Dasatinib or high-dose Imatinib for chronic-phase chronic myeloid leukemia resistant to Imatinib at a dose of 400 to 600 milligrams daily. Two-year follow-up of a randomized phase 2 study (START-R)
Kantarjian, H.
;
Pasquini, R.
;
Levy, V.
;
Jootar, S.
;
Holowiecki, J.
;
Hamerschlak, N.
;
Hughes, T.
;
Bleickardt, E.
;
Dejardin, D.
;
Cortes, J.
;
Shah, N.
2016
Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients
Deininger, M.
;
Hodgson, J.
;
Shah, N.
;
Cortes, J.
;
Kim, D.
;
Nicolini, F.
;
Talpaz, M.
;
Baccarani, M.
;
Müller, M.
;
Li, J.
;
Parker, W.
;
Lustgarten, S.
;
Clackson, T.
;
Haluska, F.
;
Guilhot, F.
;
Kantarjian, H.
;
Soverini, S.
;
Hochhaus, A.
;
Hughes, T.
;
Rivera, V.
;
et al.
2013
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
Baccarani, M.
;
Deininger, M.
;
Rosti, G.
;
Hochhaus, A.
;
Soverini, S.
;
Apperley, J.
;
Cervantes, F.
;
Clark, R.
;
Cortes, J.
;
Guilhot, F.
;
Hansen-Hjorth, H.
;
Hughes, T.
;
Kantarjian, H.
;
Kim, D.
;
Larson, R.
;
Lipton, J.
;
Mahon, F.
;
Martinelli, G.
;
Mayer, J.
;
Muller, M.
;
et al.
2011
Front-Line and Salvage Therapies With Tyrosine Kinase Inhibitors and Other Treatments in Chronic Myeloid Leukemia
Cortes, J.
;
Hochhaus, A.
;
Hughes, T.
;
Kantarjian, H.
2009
Chronic myeloid leukemia: An update of concepts and management recommendations of European LeukemiaNet
Baccarani, M.
;
Cortes, J.
;
Pane, F.
;
Niederwieser, D.
;
Saglio, G.
;
Apperley, J.
;
Cervantes, F.
;
Deininger, M.
;
Gratwohl, A.
;
Guilhot, F.
;
Hochhaus, A.
;
Horowitz, M.
;
Hughes, T.
;
Kantarjian, H.
;
Larson, R.
;
Radich, J.
;
Simonsson, B.
;
Silver, R.
;
Goldman, J.
;
Hehlmann, R.
2011
Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results
Kantarjian, H.
;
Giles, F.
;
Bhalla, K.
;
Pinilla-Ibarz, J.
;
Larson, R.
;
Gattermann, N.
;
Ottmann, O.
;
Hochhaus, A.
;
Radich, J.
;
Saglio, G.
;
Hughes, T.
;
Martinelli, G.
;
Kim, D.
;
Shou, Y.
;
Gallagher, N.
;
Blakesley, R.
;
Baccarani, M.
;
Cortes, J.
;
le Coutre, P.
2011
Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cells
Tang, M.
;
Gonen, M.
;
Quintas-Cardama, A.
;
Cortes, J.
;
Kantarjian, H.
;
Field, C.
;
Hughes, T.
;
Branford, S.
;
Michor, F.
2014
Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study
Baccarani, M.
;
Druker, B.
;
Branford, S.
;
Kim, D.
;
Pane, F.
;
Mongay, L.
;
Mone, M.
;
Ortmann, C.
;
Kantarjian, H.
;
Radich, J.
;
Hughes, T.
;
Cortes, J.
;
Guilhot, F.
Discover
Author
5
Baccarani, M.
5
Hochhaus, A.
4
Guilhot, F.
4
Kim, D.
3
Deininger, M.
3
Larson, R.
3
Radich, J.
2
Apperley, J.
2
Branford, S.
2
Cervantes, F.
.
next >
Subject
5
Benzamides
5
Humans
5
Imatinib Mesylate
5
Piperazines
5
Pyrimidines
4
Leukemia, Myelogenous, Chronic, B...
4
Treatment Outcome
3
Antineoplastic Agents
3
Protein Kinase Inhibitors
3
Time Factors
.
next >
Date issued
1
2016
1
2014
1
2013
3
2011
2
2009